These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23822990)

  • 1. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
    Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
    Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
    Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
    Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
    J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of imaging test with radionuclides in the diagnosis and treatment of pheochromocytomas and paragangliomas.
    Araujo-Castro M; Pascual-Corrales E; Alonso-Gordoa T; Molina-Cerrillo J; Martínez Lorca A
    Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):614-628. PubMed ID: 36402734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
    Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
    Carrasquillo JA; Pandit-Taskar N; Chen CC
    Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
    Jungels C; Karfis I
    Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical trial for [
    Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
    J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma.
    Aktolun C; Castellani MR; Bombardieri E
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):109-11. PubMed ID: 23822987
    [No Abstract]   [Full Text] [Related]  

  • 13. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
    Gedik GK; Hoefnagel CA; Bais E; Olmos RA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
    J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
    Rufini V; Treglia G; Perotti G; Giordano A
    Hormones (Athens); 2013; 12(1):58-68. PubMed ID: 23624132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
    Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
    QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
    Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.
    Inoue T; Yoshinaga K; Morita K; Shiga T; Kanegae K; Hirata K; Okamoto S; Tamaki N
    Ann Nucl Med; 2007 Jul; 21(5):307-10. PubMed ID: 17634850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to targeted radionuclide therapy with [
    Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
    Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.